Clinical trial
Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell…
NCT00162851 · Karolinska University Hospital, Other · Completed
Key facts
| NCT number | NCT00162851 |
|---|---|
| Title | Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia |
| Official title | A Pilot Study to Evaluate the Safety of Subcutaneous Alemtuzumab (MabCampath, Campath) in Patients With B-Cell Chronic Lymphocytic Leukemia |
| Lead sponsor | Karolinska University Hospital, Other |
| Collaborators | Schering Nordiska AB |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | B-CLL |
| Intervention type | Drug |
| Interventions | alemtuzumab |
| Enrollment | 20 |
| Start date | Apr 1, 2003 |
| Completion | Jul 1, 2006 |
| First posted | Sep 13, 2005 |
| Last update posted | Jul 25, 2007 |
| Countries | Sweden |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: